@article{032f254bab194fd294088519efd2f02d,
title = "Serum heparin-binding epidermal growth factor-like growth factor (HB-EGF) as a biomarker for primary ovarian cancer",
abstract = "Ovarian cancer is the most lethal malignancy among gynaecological cancers. Although many anticancer agents have been developed for the treatment of ovarian cancer, it continues to have an extremely poor prognosis. Heparin-binding epidermal growth factor-like grown factor (HB-EGF) has been reported to be a rational therapeutic target for ovarian cancer. Here, we evaluated the clinical significance of serum HB-EGF by examining the association between prognosis and serum HB-EGF levels in patients with primary ovarian cancer. We found that high serum HBEGF concentrations were significantly associated with poor prognosis in a combined cohort of patients with all stages of ovarian cancer, as well as in a subset of patients with advanced disease. In addition, serum HB-EGF levels increased as the cancer advanced. These data suggest that serum HB-EGF may be a target for the design of novel therapies for ovarian cancer.",
author = "Kohei Miyata and Fusanori Yotsumoto and Satoshi Fukagawa and Chihiro Kiyoshima and {Sung Ouk}, Nam and Daichi Urushiyama and Tomohiro Ito and Takahiro Katsuda and Masamitsu Kurakazu and Ryota Araki and Ayako Sanui and Daisuke Miyahara and Masaharu Murata and Kyoko Shirota and Hiroshi Yagi and Tadao Takono and Kiyoko Kato and Nobuo Yaegashi and Kohei Akazawa and Masahide Kuroki and Shin'ichiro Yasunaga and Shingo Miyamoto",
note = "Funding Information: This work was supported in part by a Grant-in-Aid from the Kakihara Science and Technology Foundation (Fukuoka, Japan), a Grant-in-Aid for Young Scientists (B) (no. 227790536), and by grants from Challenging Exploratory Research (no. 26670731); Scientific Research (B) (no. 26293362); Scientific Research (C) (no. 23592470); the Central Research Institute of Fukuoka University (141011); the Center for Advanced Molecular Medicine, Fukuoka University; the Ministry of Education, Culture, Sports, Science and Technology (Tokyo, Japan); and the Princess Takamatsu Cancer Research Fund to S. Miyamoto.",
year = "2017",
month = jul,
doi = "10.21873/anticanres.11779",
language = "English",
volume = "37",
pages = "3955--3960",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",
}
